Search Results - "Blanc, R Menarguez"

6ER-001 PCSK9 inhibitors: variation in the lipid profile in a real world setting by Maray Mateos, I, Velasco Roces, L, Rodríguez Ferreras, A, Macía Rivas, L, Fernández Laguna, C, Álvarez Asteinza, C, López, Á Pieras, Zarate Tamames, B, Menarguez Blanc, R, Arias Martínez, A, Lozano Blázquez, A

“…Background and importanceThe proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i), evolocumab and alirocumab, approved by the European Medicines…”
Get full text

4CPS-108 Dabrafenib and trametinib: combination therapy for metastatic melanoma by Carriles Fernandez, C, Arias, A, Rosado María, C, Zapico García, I, Zarate Tamames, B, Menárguez Blanc, R, Lozano-Blázquez, A

“…BackgroundThe BRAF inhibitor dabrafenib and the MEK inhibitor trametinib are indicated for the treatment of patients with unresectable or metastatic melanoma…”
Get full text

5PSQ-114 Evaluation of pharmaceutical interventions performed on medication errors detected in the prescription by Carriles Fernandez, C, Zarate Tamames, B, Alaguero Calero, M, Pieras López, Á, Arias, A, Menárguez Blanc, R, Lozano-Blázquez, A

“…BackgroundPharmaceutical validation consists in verifying medical prescriptions (dosage, route of administration, pharmaceutical presentation) and checking the…”
Get full text

1ISG-017 Impact of supply problems in a hospital pharmacy service by Zarate, B, López, Á Pieras, Menárguez Blanc, R, Iglesias Carbajo, A, Álvarez Asteinza, C, Lozano Blazquez, A, Arias-Martinez, Á, Maray Mateos, I, Macía Rivas, MD, Fernández Laguna, CL

“…Background and importanceHospital management of drugs is a complicated task and it is necessary to take into account different factors, such as average…”
Get full text

5PSQ-006 Parenteral nutrition in a neonatology intensive care unit: duration and complications by Álvarez Asteinza, C, Gómez Álvarez, ME, Arias Martínez, A, Menárguez Blanc, R, López, Á Pieras, Zarate Tamames, B, Maray Mateos, I, Macía Rivas, MD, Fernández Laguna, CL, Lozano Blázquez, A

“…Background and importanceParenteral nutrition (PN) can be used in any malnourished child or anyone at risk of malnutrition. In preterm newborns, it should be…”
Get full text

5PSQ-103 Experience of antifibrotic agents in the treatment of idiopathic pulmonary fibrosis by Menárguez Blanc, R, García Jimenez, V, Rosado María, MC, Arias Martínez, A, Zárate Tamames, B, López, Á Pieras, Álvarez Asteinza, C, Maray Mateos, I, Velasco Roces, L, Fernández Laguna, CL, Lozano Blazquez, A

“…Background and importanceAntifibrotics are an important alternative for the treatment of idiopathic pulmonary fibrosis (IPF) but long term follow-up studies of…”
Get full text

5PSQ-062 Raltitrexed as an end-of-life treatment in patients with metastatic colorectal cancer by Rodríguez Ferreras, A, Zapico García, I, Lázaro López, E, Álvarez Asteinza, C, Maray Mateos, I, Menárguez Blanc, R, Arias Martínez, A, Lozano Blázquez, A

“…BackgroundRaltitrexed is approved for the treatment of advanced colorectal cancer when there is a contraindication to fluoropyrimidines. Compared to different…”
Get full text

4CPS-184 Comparison of safety and adherence of new oral therapies for the treatment of relapsing-remitting multiple sclerosis by Torròn, A Martinez, María, MC Rosado, Martínez, A Arias, Fernandez, C Carriles, Romeo, A Llorente, Blanc, R Menarguez, López, E Lázaro, Ferreras, A Rodriguez, López, A Pieras, Tamames, B Zárate, Lozano-Blazquez, A

“…BackgroundTeriflunomide and dimethylfumarate are two new oral therapies for relapsing-remitting multiple sclerosis (RRMS). Due to the increase in patients with…”
Get full text

4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis by Arias, A, Blanc, R Menárguez, Torrón, A Martínez, Fernández, C Carriles, María, MC Rosado, Roces, L Velasco, García, I Zapico, Lozano-Blázquez, A

“…BackgroundAlemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting…”
Get full text

4CPS-152 Eculizumab for dense deposit disease: increased dosage without response: a case report by Ferreras, A Rodríguez, López, E Lázaro, García, I Zapico, Fernández, C Carriles, Blanc, R Menárguez, Martínez, A Arias, Tamames, B Zárate, López, A Pieras, Roces, L Velasco, Lozano-Blázquez, A

“…BackgroundDense deposit disease (DDD) is a rare glomerulonephritis caused by uncontrolled stimulation of the alternative complement pathway. Allograft survival…”
Get full text